weight loss

Eli Lilly's retatrutide achieved 28.7% mean weight loss, matching bariatric surgery. However, competitive pressures from Novo Nordisk, Pfizer, and others are intensifying.

Novo Nordisk will present 52 abstracts on Wegovy and experimental CagriSema at European obesity congress, highlighting cardiovascular benefits and women's health data.

Boehringer's survodutide shows 16.6% weight loss in Phase 3 trial, benefiting Zealand Pharma with EUR 315M in potential milestone payments and ongoing royalties.

Boehringer Ingelheim's survodutide achieved 16.6% average weight loss in Phase III trials, with 85.1% of patients hitting ≥5% reduction targets, supporting obesity and MASH treatment potential.

Kailera Therapeutics raised $625M in largest biotech IPO since 2021, entering competitive obesity market with oral GLP-1 candidate showing 12.1% weight loss.

Intuitive Surgical's da Vinci surgical systems offer superior long-term weight-loss outcomes versus GLP-1 drugs. Strong 28% margins and double-digit revenue growth position $ISRG as overlooked obesity-market beneficiary despite 20% year-to-date decline.

Eli Lilly's new GLP-1 pill Foundayo launches April 6 with fewer restrictions than competitors. Pipeline drug retatrutide shows superior weight loss, threatening Novo Nordisk's obesity market leadership.

Novo Nordisk and United Biotechnology's experimental drug UBT251 outperformed semaglutide in phase 2 trials, delivering stronger weight loss and glucose control.

Eli Lilly discontinuing select insulin products across EU/EEA by Q2 2027 due to commercial factors. Company's experimental retatrutide shows strong diabetes and weight-loss results.

Eli Lilly's retatrutide shows strong weight loss results in trials, but HSBC downgrades stock citing overvaluation concerns.

Structure Therapeutics reports Phase 2 data for oral GLP-1 agonist aleniglipron showing 16.3% weight loss, matching injectable competitors with better tolerability.

AbbVie reports Phase 1 data for obesity treatment ABBV-295, showing 7.75%-9.79% weight loss. Stock declined despite positive results amid broader market pressure.

Roche's obesity drug petrelintide achieved 10.7% weight loss in Phase 2 trials but significantly trails GLP-1 rivals Novo Nordisk and Eli Lilly, triggering sharp stock declines.

Novo Nordisk's Kagrama showed weaker weight-loss results than Eli Lilly's Zepbound in 84-week trial, pressuring obesity growth forecasts.

Roche's petrelintide demonstrates 10.7% weight reduction in Phase II, positioning the amylin analog as a potential alternative to dominant GLP-1 drugs with favorable tolerability. Phase III trials planned.

GLP-1 receptor agonist market projected to surge from $51.9B in 2024 to $137.4B by 2030, driven by obesity prevalence and expanded therapeutic applications.

Patent strength, not clinical efficacy, will drive GLP-1 market leadership as clinical outcomes converge. Companies with robust IP portfolios may capture disproportionate market share despite comparable results.

Novo Nordisk's obesity drug UBT251 achieved 19.7% weight loss in Phase 2 trials for Chinese patients, offsetting recent setbacks from a failed competitor drug trial.

Novo Nordisk shares fell 16% after CagriSema obesity drug trial underperformed rival Eli Lilly's tirzepatide. Deutsche Bank downgraded the stock amid competitive concerns.

Viking Therapeutics surged 10.91% after Novo Nordisk's obesity drug failed against Eli Lilly's competitor. Viking's dual injectable/oral candidate VK2735 offers differentiation entering Phase 3 trials.